Lai Kai Pharmaceutical Hong Kong Stock Exchange announced that the Drug Evaluation Center of China's State Drug Administration has approved LAE102 for clinical trials of a new drug to treat obese patients.
来凯医药：LAE102用于治疗肥胖症患者的新药临床试验获国家药监局批准
Lai Kai Pharmaceutical: Clinical trial of LAE102's new drug for treating obese patients approved by the State Drug Administration
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.